Company / Gross Margin
Fulgent Genetics, Inc. Gross Margin History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Margin
40.6%
FY2025
5-year range
37.8% / 78.7%
FY2021-FY2025
Trend
+7.2%
vs FY2024
Sector context
#73 of 96
Health Care
What the data says
Fulgent Genetics, Inc.'s gross margin of 40.6% is lower than 76% of companies in the Health Care sector (FY2025). Gross Margin returned to growth in FY2025 after 2 years of decline, reaching 40.6%.
Based on SEC 10-K filings.
40.6% in FY2025 with a 5-year CAGR of -38.1%.
Declined from 78.3% to 40.6% over the past 2 years.
Health Care sector context is included.
Gross Margin over time
Growth rates
- 3-Year Change
- -38.1pp
- 5-Year Change
- -38.1pp
- 10-Year Change
- -
Sector benchmark
Bottom 24% in Health CareTop 76% of 96This company 40.6% Sector average 53.6%
▼
-24.3% below sector average
Key checks
Key Insights
- In FY2025, gross margin increased 7.2% year-over-year.
- Currently 13.0pp below the Health Care sector average.
- Peak gross margin was recorded in FY2017.
- Lowest gross margin in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 5.28 (safe zone, above 2.9 threshold)
- Negative profit margin: -15.1%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | 40.6% | +7.2% |
| FY2024 | 37.8% | -51.7% |
| FY2023 | 78.3% | -0.5% |
| FY2022 | 78.7% | +39.0% |
| FY2021 | 56.6% | -28.0% |
| FY2020 | 78.7% | +57.7% |
| FY2019 | 49.9% | -8.2% |
| FY2018 | 54.4% | -71.7% |
| FY2017 | 191.8% | +616.9% |
| FY2016 | 26.8% | -43.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026